China-based Innovent Biologics Inc., (HKG: 1801) has entered into a clinical study and supply cooperation agreement with compatriot firm RemeGen (HKG: 9995). The collaboration will pair Innovent’s programmed death-1 (PD-1) inhibitor Tyvyt (sintilimab injection) with RemeGen’s antibody drug conjugate (ADC) drug candidates RC88 and RC108 in a clinical study.<\/p>\n\n\n\n
Clinical Trial Collaboration Details<\/strong> Sintilimab’s Background and Indications<\/strong>
As per the agreement, Innovent will provide clinical drug supplies of sintilimab for the trial. RemeGen will conduct Phase I\/IIa clinical studies to evaluate the anti-tumor activity and safety of the combination therapy of sintilimab with RC88 or RC108 in Chinese patients with advanced solid tumors.<\/p>\n\n\n\n
Sintilimab, co-developed by Innovent and Eli Lilly and Company, is an innovative PD-1 inhibitor. In China, sintilimab has been approved for seven indications and included in the National Reimbursement Drug List (NRDL) for six indications. It is the sole PD-1 inhibitor for the first-line treatment of five high-incidence cancer types in the NRDL, including non-squamous NSCLC, squamous NSCLC, hepatocellular carcinoma, esophageal squamous cell carcinoma, and gastric cancer. It is also the first and only immunotherapy medicine for gastric cancer in the NRDL.<\/p>\n\n\n\n